Not all weight loss drugs are injectable — here's what's actually available in the UK

The myth: every modern weight-loss medicine means a needle

It's a reasonable assumption to arrive at. Coverage of Mounjaro and Wegovy has been almost entirely injection-focused, and for much of the last few years that picture was accurate, the most clinically significant licensed options in the UK were weekly subcutaneous injections. But the landscape shifted in June 2026 when the MHRA approved Wegovy tablets, making oral semaglutide the first oral GLP-1 medicine licensed in the UK for weight management. The UK was the first country in Europe to grant that approval.

Orlistat, meanwhile, has never involved a needle at all. It's a capsule taken with meals, working by blocking an enzyme in the gut rather than targeting appetite hormones. It's been available in both prescription and lower-strength pharmacy-only forms for years. The NHS orlistat page covers how it's used and who it suits.

So the accurate answer to the question is: injections are currently the most widely discussed format because the trial evidence behind tirzepatide and semaglutide is substantial and the weight-loss results are larger than those seen with older medicines, but they are not the only option, and they haven't been for a while. If you're also curious about newer pipeline treatments, you can read more about weight loss injections reta as an emerging area worth understanding.

What the injectable options actually involve, and why many people find them manageable

Mounjaro (tirzepatide) and Wegovy (semaglutide) are both once-weekly subcutaneous injections. Subcutaneous means the needle goes into fatty tissue just under the skin (the abdomen, thigh or upper arm) rather than into a vein or muscle. The pens are pre-filled and pre-set, so there's no drawing up of liquid or manual dosing. Most people find the technique straightforward once they've read the instructions or watched a demonstration.

Mounjaro's KwikPen contains four weekly doses; Wegovy comes as individual weekly pens. Treatment starts at a low dose and is increased gradually by a prescriber, which helps the body adjust and keeps side effects manageable. If injections are a concern (needle anxiety is genuinely common and nothing to be embarrassed about) it's worth raising that at consultation, because it may affect which treatment is the better fit.

A question our prescribers hear fairly regularly: does an injection leave a mark or require clinical facilities? The answer is no on both counts. These are small, thin-needle self-administered pens used at home. Some people time their weekly dose around a routine, payday or a Monday order, whatever makes the habit stick. The side effects of injectable weight loss drugs are worth understanding before you start, and are covered in detail separately.

The oral alternative: what Wegovy tablets offer and where they sit

Wegovy tablets contain semaglutide, the same active ingredient as the Wegovy injection, co-formulated with an absorption enhancer called SNAC that allows the molecule to pass through the stomach wall. The licensed maintenance dose is 25mg once daily, reached through a gradual escalation starting at 1.5mg. Crucially, no refrigeration is needed, the tablets store at room temperature, which many people find more practical for travel or work.

The difference between the injection and tablet routes goes beyond convenience. Trial data from the OASIS 4 study reported an average weight loss of around 13.6% over 64 weeks for participants taking the tablet, rising to approximately 17% among those who adhered fully to treatment. That compares to around 15% average reduction seen in the STEP 1 trial for the 2.4mg weekly injection, as summarised on the NHS semaglutide page. The tablet's results are meaningful, though the injection's are generally larger, a difference that a prescriber will weigh against individual circumstances.

Wegovy tablets are not available on the NHS yet; a NICE appraisal would need to happen first. They require a private prescription following clinical assessment. Rybelsus, the other oral semaglutide tablet, is licensed for type 2 diabetes at different doses, it is not the same product and should not be treated as an equivalent.

Which format suits which person, and what the consultation is actually for

There's no single answer here, and that's precisely why clinical assessment matters. The choice of injectable or oral weight loss medicine depends on factors including your BMI, any weight-related health conditions, other medicines you take, and practical preferences. Needle anxiety, travel schedules, dietary habits (the tablet must be taken on an empty stomach with water, at least 30 minutes before food) and absorption considerations all come into the conversation.

For context on cost (because format affects price) the cost of weight-loss injections varies by dose and provider; oral options are priced differently again. Comparing the two on price alone misses the clinical question of which is appropriate.

At nume, a GPhC-registered Independent Prescriber reviews every consultation personally. Our pharmacy holds GPhC registration 9012878, verifiable directly at the GPhC register. If you're unsure whether an injection or a tablet is the right starting point, the consultation is the place to work that through, not a guess made before you've spoken to anyone clinical.